Firstly, given the finding that ARHGEF2 amplification occurs in ~30% CRPC patients, which in a way may explain the upregulation was observed in CRPC patients when compared with primary PCa patients; however, the mechanisms behind this genetic change (ARHGEF2 amplification) still need to be further studied. Here, ARHGEF2 is linked to posterior cortical atrophy.